Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8317516rdf:typepubmed:Citationlld:pubmed
pubmed-article:8317516lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0038317lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0019080lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0009905lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C2364326lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:8317516lifeskim:mentionsumls-concept:C0449774lld:lifeskim
pubmed-article:8317516pubmed:issue6 Pt 1lld:pubmed
pubmed-article:8317516pubmed:dateCreated1993-7-28lld:pubmed
pubmed-article:8317516pubmed:abstractTextOur purpose was to determine the relationship between bioavailability of contraceptive steroids and bleeding patterns.lld:pubmed
pubmed-article:8317516pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:languageenglld:pubmed
pubmed-article:8317516pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8317516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8317516pubmed:statusMEDLINElld:pubmed
pubmed-article:8317516pubmed:monthJunlld:pubmed
pubmed-article:8317516pubmed:issn0002-9378lld:pubmed
pubmed-article:8317516pubmed:authorpubmed-author:CechT RTRlld:pubmed
pubmed-article:8317516pubmed:authorpubmed-author:ZacurH AHAlld:pubmed
pubmed-article:8317516pubmed:authorpubmed-author:BurkmanR TRTlld:pubmed
pubmed-article:8317516pubmed:authorpubmed-author:KimballA WAWlld:pubmed
pubmed-article:8317516pubmed:authorpubmed-author:SalehW AWAlld:pubmed
pubmed-article:8317516pubmed:authorpubmed-author:KwiterovichPPlld:pubmed
pubmed-article:8317516pubmed:issnTypePrintlld:pubmed
pubmed-article:8317516pubmed:volume168lld:pubmed
pubmed-article:8317516pubmed:ownerNLMlld:pubmed
pubmed-article:8317516pubmed:authorsCompleteYlld:pubmed
pubmed-article:8317516pubmed:pagination1740-5; discussion 1745-7lld:pubmed
pubmed-article:8317516pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8317516pubmed:otherAbstractPIP: Breakthrough bleeding as a side effect of oral contraceptive (OC) use is considered one of the primary causes if discontinuation of oral contraceptives. In this study, the incidence and pattern of vaginal bleeding is examined and correlated with biologic responses and plasma steroid bioavailability. Between October 1, 1985 and October 15, 1987, subjects were randomly selected from eligible women beginning OC use as patients of the Department of Gynecology and Obstetrics at the Johns Hopkins Medical Institutions. Women were grouped by type of OC as follows: 1) 67 women taking 50 micrograms of ethinyl estradiol and 1.0 mg of norethindrone (OC1);l 2) 61 women taking 35 micrograms of ethinyl estradiol and 1.0 mg of norethindrone (OC2); and 3) 64 women taking 35 micrograms of ethinyl estradiol and .5 mg of norethindrone (OC3). Estrogen and progesterone concentrations in plasma were measured on the 21st day during the third, sixth, and ninth cycles. The samples was taken 24 hours after ingestion of the pill for day 20, and 1 hour after taking the pill on day 21. An extensive interview was also conducted for all study participants. Bleeding was recorded for any amount of bleeding occurring during days 2 through 21, and during days 21 through 28. Cycles were omitted where pills had been forgotten by the patient. An initial slope was calculated with the 1 hour value level and subtracting the 0 hour level over the actual time interval. Linear regression analysis was used to compare the slopes and bleeding days. Of the 316 women enrolled, 61% (192) completed the study. The findings were that the incidence of intermenstrual bleeding was not statistically different among the various preparations. For 59 patients eliminated from the study, 24% experienced intermenstrual bleeding. Those lose to follow-up were not among those unwilling to tolerate their bleeding pattern. There was similar incidence of other side effects among all three preparations: .5% amenorrhea of dysmenorrhea, 7% nausea, 16% headache, 26.5% depressed mood, 16.6% breast tenderness, and 44.3% acne. The low-dose OC3 had the statistically highest rates of intermenstrual bleeding. The bleeding patterns are described. Bleeding patterns were higher than those previously reported in the literature. Further research might focus on controlling for factors such as hormone-binding globulin capacity.lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:meshHeadingpubmed-meshheading:8317516-...lld:pubmed
pubmed-article:8317516pubmed:year1993lld:pubmed
pubmed-article:8317516pubmed:articleTitleA randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.lld:pubmed
pubmed-article:8317516pubmed:affiliationDepartment of Gynecology and Obstetrics, Henry Ford Hospital, Detroit, MI 48202.lld:pubmed
pubmed-article:8317516pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8317516pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8317516pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8317516pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8317516pubmed:publicationTypeRandomized Controlled Triallld:pubmed